Skip to main content
. 2023 Jan 16;81(3):224–234. doi: 10.1016/j.jacc.2022.10.030

Figure 4.

Figure 4

Figure 4

Primary Endpoint Marginal Probabilities and Biomarker Changes According to Treatment Arm

(A) Individual marginal probabilities of death or need for intubation in the PCSK9 inhibitor or placebo arm across levels of baseline serum IL-6. Serum IL-6 concentrations (B) and low-density lipoprotein cholesterol (LDL-C) levels (C) at baseline and at 7 and 30 days after randomization in the PCSK9 inhibitor and placebo arms. (D) Waterfall plot for greatest percent change in serum IL-6 levels with PCSK9 inhibitor or placebo up to 30 days compared with baseline. ∗Denotes need for intubation. †Denotes a fatal event. Inh = inhibitor; other abbreviations as in Figure 2.